“即便疗法的开发取得众多进展，惰性和侵袭性NHL患者随着每次复发，控制疾病的挑战日益增加，“罗氏首席医学官兼全球产品开发负责人Levi Garrayway医学博士说：”这些早期数据意味着，我们的创新双特异性癌症免疫疗法，可以为需要更多选择的复发/难治性患者提供帮助。“

参考资料：

[1] Ash 2019 – Roche doesn’t disappoint with bispecific. Retrieved December 8, 2019, from https://www.evaluate.com/vantage/articles/events/conferences/ash-2019-roche-doesnt-disappoint-bispecific

[2] Genentech Announces New Data on Novel Cd20-cd3 Bispecific Cancer Immunotherapies in People With Difficult-to-Treat Lymphomas. Retrieved December 8, 2019, from https://www.businesswire.com/news/home/20191207005029/en

原标题：ASH | CAR-T疗法无效患者也能治，罗氏CD20-CD3双特异性抗体初步临床结果积极

▽关注【药明康德】微信公众号